Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428015 | 0.88 | CA12 (0.47) | CA12CA1CA9IDO1SYK | |
| SCHEMBL1137026 | 0.88 | CA12 (0.47) | CA12CA1CA9IDO1SYK | |
| SCHEMBL30681937 | 0.86 | HPGD (0.51) | CA12CA1CA9SYKCYP17A1 | |
| SCHEMBL941486 | 0.86 | HPGD (0.51) | CA12CA1CA9SYKCYP17A1 | |
| SCHEMBL6096909 | 0.83 | CA1 (0.48) | CA12CA1CA9CYP17A1HDAC3 | |
| SCHEMBL2349732 | 0.83 | CA12 (0.54) | CA12CA1CA9CYP17A1HDAC3 | |
| SCHEMBL6816071 | 0.83 | CA12 (0.48) | CA12CA1CA9SYKCYP17A1 | |
| SCHEMBL4612314 | 0.83 | CA12 (0.48) | CA12CA1CA9CYP17A1HDAC3 | |
| SCHEMBL31214788 | 0.83 | CA12 (0.54) | CA12CA1CA9CYP17A1HDAC3 | |
| SCHEMBL29537539 | 0.83 | CA12 (0.48) | CA12CA1CA9SYKCYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970264-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9073922-B2 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2014151444-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012066065-A1 | PHENYL-HETEROARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| CN-100471842-C | Carbostyril derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2009-03-25 | — | — | CN | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| CN-1826321-A | Quinolone derivative or its salt | YAMANOUCHI PHARMA CO LTD (JP) | 2006-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | CA12 4470/4885CA1 4010/4885CA9 665/4885 |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | CA12 4187/4885CA1 3644/4885CA9 416/4885 |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | CA12 4547/4885CA1 4429/4885CA9 3347/4885 |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | CA12 4246/4885CA1 2756/4885CA9 2173/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | CA12 1414/4885CA1 1874/4885CA9 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.